115 related articles for article (PubMed ID: 24801822)
1. Loss of ERβ expression in papillary thyroid carcinoma is associated with recurrence in young female.
Ahn HY; Kim MS; Kim MJ; Cho SY; Kim YA; Lee GH; Lee BC; Park YJ; Yi KH
Clin Endocrinol (Oxf); 2015 Feb; 82(2):300-6. PubMed ID: 24801822
[TBL] [Abstract][Full Text] [Related]
2. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
Ahn HY; Song RY; Ahn HS; Kim HS
Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
[TBL] [Abstract][Full Text] [Related]
3. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of oestrogen receptor-β is associated with tumour invasion and metastasis in oestrogen receptor-α-negative human papillary thyroid carcinoma.
Dong WW; Li J; Li J; Zhang P; Wang ZH; Sun W; Zhang H
Int J Exp Pathol; 2018 Feb; 99(1):15-21. PubMed ID: 29655286
[TBL] [Abstract][Full Text] [Related]
5. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.
de Castro TP; Waissmann W; Simões TC; de Mello RC; Carvalho DP
Clin Endocrinol (Oxf); 2016 Sep; 85(3):466-74. PubMed ID: 26834009
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
[TBL] [Abstract][Full Text] [Related]
7. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma.
Roh JL; Park JW; Jeong J; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2017 Sep; 116(4):450-458. PubMed ID: 28608492
[TBL] [Abstract][Full Text] [Related]
8. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.
Huang Y; Dong W; Li J; Zhang H; Shan Z; Teng W
BMC Cancer; 2014 May; 14():383. PubMed ID: 24884830
[TBL] [Abstract][Full Text] [Related]
9. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
10. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
11. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma.
Jin BJ; Kim MK; Ji YB; Song CM; Park JH; Tae K
Oral Oncol; 2015 Aug; 51(8):759-63. PubMed ID: 26093388
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of recurrent papillary thyroid cancer.
Zhu J; Wang X; Zhang X; Li P; Hou H
Diagn Pathol; 2015 Jul; 10():96. PubMed ID: 26168921
[TBL] [Abstract][Full Text] [Related]
16. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer.
Qu N; Zhang L; Wu WL; Ji QH; Lu ZW; Zhu YX; Lin DZ
Tumour Biol; 2016 Jul; 37(7):8783-9. PubMed ID: 26743781
[TBL] [Abstract][Full Text] [Related]
17. The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas.
Zeng Q; Chen G; Vlantis A; Tse G; van Hasselt C
J Pathol; 2008 Mar; 214(4):425-33. PubMed ID: 18085520
[TBL] [Abstract][Full Text] [Related]
18. Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.
Gorshtein A; Benbassat C; Robenshtok E; Shimon I; Hirsch D
World J Surg; 2016 Sep; 40(9):2123-30. PubMed ID: 27094559
[TBL] [Abstract][Full Text] [Related]
19. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
Baek SK; Jung KY; Kang SM; Kwon SY; Woo JS; Cho SH; Chung EJ
Thyroid; 2010 Feb; 20(2):147-52. PubMed ID: 19785522
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
